Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 39

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

DOPAL initiates αSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson’s disease

Masato, Anna, Plotegher, Nicoletta, Terrin, Francesca, Sandre, Michele, Faustini, Gaia, Thor, Andrea, Adams, Stephen, Berti, Giulia, Cogo, Susanna, De Lazzari, Federica, Fontana, Camilla Maria, Martinez, Paul Anthony, Strong, Randy, Bandopadhyay, Rina, Bisaglia, Marco, Bellucci, Arianna, Greggio, Elisa, Dalla Valle, Luisa, Boassa, Daniela, Bubacco, Luigi · 2023 · npj Parkinson's Disease

Abstract

Dopamine dyshomeostasis has been acknowledged among the determinants of nigrostriatal neuron degeneration in Parkinson’s disease (PD). Several studies in experimental models and postmortem PD patients underlined increasing levels of the dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL), which is highly reactive towards proteins. DOPAL has been shown to covalently modify the presynaptic protein αSynuclein (αSyn), whose misfolding and aggregation represent a major trait of PD pathology, triggering αSyn oligomerization in dopaminergic neurons. Here, we demonstrated that DOPAL elicits αSyn accumulation and hampers αSyn clearance in primary neurons. DOPAL-induced αSyn buildup lessens neuronal resilience, compromises synaptic integrity, and overwhelms protein quality control pathways in neurites. The progressive decline of neuronal homeostasis further leads to dopaminergic neuron loss and motor impairment, as showed in in vivo models. Finally, we developed a specific antibody which detected increased DOPAL-modified αSyn in human striatal tissues from idiopathic PD patients, corroborating the translational relevance of αSyn-DOPAL interplay in PD neurodegeneration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41531-023-00485-1

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 81

  1. Brichta, L. & Greengard, P. Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update. Front. Neuroanat. 8, 152 (2014). · DOI · Paper page
  2. Surmeier, D. J., Obeso, J. A. & Halliday, G. M. Selective neuronal vulnerability in Parkinson disease. Nat. Rev. Neurosci. 18, 101–113 (2017). · DOI · Paper page
  3. Bolam, J. P. & Pissadaki, E. K. Living on the edge with too many mouths to feed: Why dopamine neurons die. Mov. Disord. 27, 1478–1483 (2012). · DOI · Paper page
  4. Graves, S. M. et al. Dopamine metabolism by a monoamine oxidase mitochondrial shuttle activates the electron transport chain. Nat. Neurosci. 23, 15–20 (2020). · DOI · Paper page
  5. Wang, Y.-C., Lauwers, E. & Verstreken, P. Presynaptic protein homeostasis and neuronal function. Curr. Opin. Genet. Dev. 44, 38–46 (2017). · DOI
  6. Janezic, S. et al. Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc. Natl Acad. Sci. USA 110, E4016–E4025 (2013). · DOI · Paper page
  7. Mor, D. E. et al. Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration. Nat. Neurosci. 20, 1560–1568 (2017). · DOI · Paper page
  8. Wegrzynowicz, M. et al. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model. Acta Neuropathol. 138, 1–21 (2019). · DOI
  9. Goldstein, D. S. et al. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson’s disease. J. Neurochem. 126, 591–603 (2013). · DOI · Paper page
  10. Burke, W. J., Li, S. W., Williams, E. A., Nonneman, R. & Zahm, D. S. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson’s disease pathogenesis. Brain Res. 989, 205–213 (2003). · DOI · Paper page
  11. Masato, A., Plotegher, N., Boassa, D. & Bubacco, L. Impaired dopamine metabolism in Parkinson’s disease pathogenesis. Mol. Neurodegener. 14, 35 (2019). · DOI · Paper page
  12. Cruz, F. & Edmondson, D. E. Kinetic properties of recombinant MAO-A on incorporation into phospholipid nanodisks. J. Neural Transm. 114, 699–702 (2007). · doi:10.1007/s00702-007-0673-0
  13. Umek, N., Geršak, B., Vintar, N., Šoštarič, M. & Mavri, J. Dopamine autoxidation is controlled by acidic pH. Front. Mol. Neurosci. 11, 467 (2018). · DOI
  14. Salomäki, M., Marttila, L., Kivelä, H., Ouvinen, T. & Lukkari, J. Effects of pH and oxidants on the first steps of polydopamine formation: a thermodynamic approach. J. Phys. Chem. B 122, 6314–6327 (2018). · DOI · Paper page
  15. Rees, J. N., Florang, V. R., Eckert, L. L. & Doorn, J. A. Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. Chem. Res. Toxicol. 22, 1256–1263 (2009). · DOI
  16. Pifl, C. et al. Is Parkinson’s disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum. J. Neurosci. 34, 8210–8218 (2014). · DOI · Paper page
  17. Nicotra, A., Pierucci, F., Parvez, H. & Senatori, O. Monoamine oxidase expression during development and aging. NeuroToxicology 25, 155–165 (2004). · DOI · Paper page
  18. Grunblatt, E. et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural Transm. 111, 1543–1573 (2004). · DOI · Paper page
  19. Mandel, S. A., Fishman, T. & Youdim, M. B. H. Gene and protein signatures in sporadic Parkinson’s disease and a novel genetic model of PD. Parkinsonism Relat. Disord. 13, S242–S247 (2007). · DOI
  20. Plotegher, N. et al. DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function. Sci. Rep. 7, 40699 (2017). · DOI · Paper page
  21. Burke, W. J. et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 115, 193–203 (2008). · DOI · Paper page
  22. Follmer, C. et al. Oligomerization and membrane-binding properties of covalent adducts formed by the interaction of a-synuclein with the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL). J. Biol. Chem. 290, 27660–27679 (2015). · DOI · Paper page
  23. Mazzulli, J. R., Armakola, M., Dumoulin, M., Parastatidis, I. & Ischiropoulos, H. Cellular oligomerization of α-Synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence. J. Biol. Chem. 282, 31621–31630 (2007). · DOI
  24. Mazzulli, J. R., Burbulla, L. F., Krainc, D. & Ischiropoulos, H. Detection of free and protein-bound ortho-quinones by near-infrared fluorescence. Anal. Chem. 88, 2399–2405 (2016). · DOI
  25. Fellman, J. H. The rearrangement of epinephrine. Nature 182, 311–312 (1958). · doi:10.1038/182311a0
  26. Kumar, S. T. et al. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology. Neurobiol. Dis. 146, 105086 (2020). · DOI
  27. Butko, M. T. et al. Fluorescent and photo-oxidizing TimeSTAMP tags track protein fates in light and electron microscopy. Nat. Neurosci. 15, 1742–1751 (2012). · DOI
  28. Ellisman, M. H. et al. Advances in molecular probe-based labeling tools and their application to multiscale multimodal correlated microscopies. J. Chem. Biol. 8, 143–151 (2015). · DOI
  29. Utton, M. A., Noble, W. J., Hill, J. E., Anderton, B. H. & Hanger, D. P. Molecular motors implicated in the axonal transport of tau and α-synuclein. J. Cell Sci. 118, 4645–4654 (2005). · DOI · Paper page
  30. Shu, X. et al. A genetically encoded tag for correlated light and electron microscopy of intact cells, tissues, and organisms. PLoS Biol. 9, e1001041 (2011). · DOI · Paper page
  31. Boassa, D. et al. Mapping the subcellular distribution of -synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson’s disease pathogenesis. J. Neurosci. 33, 2605–2615 (2013). · DOI
  32. Burré, J. The synaptic function of α-synuclein. J. Parkinsons Dis. 5, 699–713 (2015). · DOI · Paper page
  33. Logan, T., Bendor, J., Toupin, C., Thorn, K. & Edwards, R. H. α-Synuclein promotes dilation of the exocytotic fusion pore. Nat. Neurosci. 20, 681–689 (2017). · DOI · Paper page
  34. Fusco, G., Sanz-Hernandez, M. & De Simone, A. Order and disorder in the physiological membrane binding of α-synuclein. Curr. Opin. Struct. Biol. 48, 49–57 (2018). · DOI
  35. Wang, L. et al. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J. Neurosci. 28, 3384–3391 (2008). · DOI · Paper page
  36. Boassa, D. et al. Split-miniSOG for spatially detecting intracellular protein-protein interactions by correlated light and electron microscopy. Cell Chem. Biol. 26, 1407–1416.e5 (2019). · DOI
  37. Alvarez-Erviti, L. et al. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol. Dis. 42, 360–367 (2011). · DOI · Paper page
  38. Danzer, K. M. et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 7, 42 (2012). · DOI · Paper page
  39. Binns, T. C. et al. Rational design of bioavailable photosensitizers for manipulation and imaging of biological systems. Cell Chem. Biol. 27, 1063–1072.e7 (2020). · DOI
  40. Tofaris, G. K. et al. Ubiquitin ligase Nedd4 promotes α-synuclein degradation by the endosomal-lysosomal pathway. Proc. Natl Acad. Sci. USA 108, 17004–17009 (2011). · DOI · Paper page
  41. Morgan, C. A., Parajuli, B., Buchman, C. D., Dria, K. & Hurley, T. D. N,N-diethylaminobenzaldehyde (DEAB) as a substrate and mechanism-based inhibitor for human ALDH isoenzymes. Chem. Biol. Interact. 234, 18–28 (2015). · DOI
  42. Wey, M. C.-Y. et al. Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson’s disease. PLoS ONE 7, e31522 (2012). · DOI · Paper page
  43. Lam, J. P., Mays, D. C. & Lipsky, J. J. Inhibition of recombinant human mitochondrial and cytosolic aldehyde dehydrogenases by two candidates for the active metabolites of disulfiram. Biochemistry 36, 13748–13754 (1997). · DOI
  44. Legros, H., Dingeval, M.-G., Janin, F., Costentin, J. & Bonnet, J.-J. Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: relationships with 3,4-dihydroxyphenylacetaldehyde formation. Neurotoxicology 25, 365–375 (2004). · doi:10.1016/s0161-813x(03)00148-7
  45. Laplane, D., Attal, N., Sauron, B., De Billy, A. & Dubois, B. Lesions of basal ganglia due to disulfiram neurotoxicity. Neurosurg. Psychiatry 55, 925–929 (1992). · DOI
  46. Sun, Z. & Gitler, A. D. Discovery and characterization of three novel synuclein genes in zebrafish. Dev. Dyn. 237, 2490–2495 (2008). · DOI
  47. Toni, M. & Cioni, C. Fish synucleins: an update. Mar. Drugs 13, 6665–6686 (2015). · DOI
  48. Lulla, A. et al. Neurotoxicity of the Parkinson disease-associated pesticide ziram is synuclein-dependent in zebrafish embryos. Environ. Health Perspect. 124, 1766–1775 (2016). · DOI
  49. Fitzmaurice, A. G. et al. Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proc. Natl Acad. Sci. USA 110, 636–641 (2013). · DOI · Paper page
  50. Du, Y. et al. Spatial and temporal distribution of dopaminergic neurons during development in zebrafish. Front Neuroanat. 10, 115 (2016). · DOI
  51. Kroll, F. et al. A simple and effective f0 knockout method for rapid screening of behaviour and other complex phenotypes. Elife 10, 1–34 (2021). · DOI · Paper page
  52. Caudle, W. M. et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 27, 8138–8148 (2007). · DOI · Paper page
  53. Conway, K. A., Rochet, J. C., Bieganski, R. M. & Lansbury, P. T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 1346–1349 (2001). · DOI · Paper page
  54. Mazzulli, J. R. et al. Cytosolic catechols inhibit -synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J. Neurosci. 26, 10068–10078 (2006). · DOI
  55. Bisaglia, M. et al. Dopamine quinones interact with α-synuclein to form unstructured adducts. Biochem. Biophys. Res. Commun. 394, 424–428 (2010). · DOI
  56. Rekas, A. et al. The structure of dopamine induced -synuclein oligomers. Eur. Biophys. J. 39, 1407–1419 (2010). · DOI
  57. Pantazopoulou, M. et al. Distinct alpha‐Synuclein species induced by seeding are selectively cleared by the Lysosome or the Proteasome in neuronally differentiated SH‐SY5Y cells. J. Neurochem. 156, 880–896 (2021). · DOI
  58. Li, W. et al. Stabilization of α-synuclein protein with aging and familial Parkinson’s disease-linked A53T mutation. J. Neurosci. 24, 7400–7409 (2004). · DOI · Paper page
  59. Martinez-Vicente, M. et al. Dopamine-modified α-synuclein blocks chaperone-mediated autophagy. J. Clin. Investig. 118, 777–778 (2008).
  60. Stykel, M. G. et al. α-Synuclein mutation impairs processing of endomembrane compartments and promotes exocytosis and seeding of α-synuclein pathology. Cell Rep. 35, 109099 (2021). · DOI
  61. Plotegher, N. & Bubacco, L. Lysines, Achilles’ heel in alpha-synuclein conversion to a deadly neuronal endotoxin. Ageing Res. Rev. 26, 62–71 (2016). · DOI
  62. Tozzi, A. et al. Dopamine-dependent early synaptic and motor dysfunctions induced by α-synuclein in the nigrostriatal circuit. Brain 144, 3477–3491 (2021). · DOI
  63. Hallengren, J., Chen, P.-C. & Wilson, S. M. Neuronal ubiquitin homeostasis. Cell Biochem. Biophys. 67, 67–73 (2013). · DOI
  64. Boecker, C. A. & Holzbaur, E. L. Vesicular degradation pathways in neurons: at the crossroads of autophagy and endo-lysosomal degradation. Curr. Opin. Neurobiol. 57, 94–101 (2019). · DOI
  65. Kageyama, S. et al. p62/SQSTM1-droplet serves as a platform for autophagosome formation and anti-oxidative stress response. Nat. Commun. 12, 16 (2021). · DOI · Paper page
  66. Kuusisto, E., Parkkinen, L. & Alafuzoff, I. Morphogenesis of Lewy bodies: dissimilar incorporation of α-synuclein, ubiquitin, and p62. J. Neuropathol. Exp. Neurol. 62, 1241–1253 (2003). · DOI · Paper page
  67. Shahmoradian, S. H. et al. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 22, 1099–1109 (2019). · DOI · Paper page
  68. Mahul-Mellier, A. L. et al. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc. Natl Acad. Sci. USA 117, 4971–4982 (2020). · DOI · Paper page
  69. Koppaka, V. et al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharm. Rev. 64, 520–539 (2012). · DOI · Paper page
  70. Bellucci, A. et al. Redistribution of DAT/α-synuclein complexes visualized by “in situ” proximity ligation assay in transgenic mice modelling early Parkinson’s disease. PLoS ONE 6, e27959 (2011). · doi:10.1371/journal.pone.0027959
  71. Giordano, N. et al. Motor learning and metaplasticity in striatal neurons: relevance for Parkinson’s disease. Brain 141, 505–520 (2018). · DOI
  72. Salas-Leal, A. C. et al. rs3764435 associated with Parkinson’s disease in Mexican mestizos: case-control study reveals protective effects against disease development and cognitive impairment. Front. Neurol. 10, 1066 (2019). · DOI
  73. Fan, H.-H. et al. An antisense Alu transposon insertion/deletion polymorphism of ALDH1A1 may functionally associate with Parkinson’s disease. BMC Geriatr. 22, 1–10 (2022). · DOI
  74. Zhao, H. et al. Alpha-synuclein dopaminylation presented in plasma of both healthy subjects and Parkinson’s disease patients. Proteom. Clin. Appl. 14, e1900117 (2020). · DOI
  75. Masato, A., Sandre, M., Antonini, A. & Bubacco, L. Patients stratification strategies to optimize the effectiveness of scavenging biogenic aldehydes: towards a neuroprotective approach for Parkinson’s disease. Curr. Neuropharmacol. 19, 1618–1639 (2021). · DOI
  76. Meerbrey, K. L. et al. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc. Natl Acad. Sci. USA 108, 3665–3670 (2011). · DOI · Paper page
  77. López-Jiménez, A. et al. A spontaneous deletion of α-Synuclein is associated with an increase in CB1 mRNA transcript and receptor expression in the hippocampus and amygdala: effects on alcohol consumption. Synapse 67, 280–289 (2013). · doi:10.1002/syn.21639
  78. Zaltieri, M. et al. α-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons. J. Cell Sci. 128, 2231–2243 (2015). · DOI · Paper page
  79. Berkhoudt Lassen, L. et al. ELISA method to detect α-synuclein oligomers in cell and animal models. PLoS ONE 13, e0196056 (2018). · DOI
  80. Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B. & Schilling, T. F. Stages of embryonic development of the zebrafish. Dev. Dyn. 203, 253–310 (1995). · DOI · Paper page
  81. Mamais, A. et al. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson’s disease brains with Lewy Body pathology compared to idiopathic cases. Neurobiol. Dis. 58, 183–190 (2013). · DOI

Cited by

See all 39

Metadata

Authors
Masato, A., Plotegher, N., Terrin, F., Sandre, M., Faustini, G., Thor, A., Adams, S., Berti, G., Cogo, S., De Lazzari, F., Fontana, C. M., Martinez, P. A., Strong, R., Bandopadhyay, R., Bisaglia, M., Bellucci, A., Greggio, E., Dalla Valle, L., Boassa, D., & Bubacco, L.
Venue
npj Parkinson's Disease
Published
2023-03-25
Volume
9
Issue
1
ISSN
2373-8057
Cited by
39
References
8
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DOPAL initiates αSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson’s disease. https://app.cochat.ai/papers/10.1038/s41531-023-00485-1
The paper
Masato, A., Plotegher, N., Terrin, F., Sandre, M., Faustini, G., Thor, A., Adams, S., Berti, G., Cogo, S., De Lazzari, F., Fontana, C. M., Martinez, P. A., Strong, R., Bandopadhyay, R., Bisaglia, M., Bellucci, A., Greggio, E., Dalla Valle, L., Boassa, D., & Bubacco, L. (2023). DOPAL initiates αSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson’s disease. npj Parkinson's Disease. https://doi.org/10.1038/s41531-023-00485-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.